Investing.com - Novo Nordisk ADR (NYSE: NVO) reported second quarter EPS of $10.17, $9.46 better than the analyst estimate of $0.71. Revenue for the quarter came in at $133.41B versus the consensus estimate of $9.98B.
Novo Nordisk ADR's stock price closed at $130.12. It is up 1.32% in the last 3 months and up 37.57% in the last 12 months.
Novo Nordisk ADR saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Novo Nordisk ADR's stock price’s past reactions to earnings here.
According to InvestingPro, Novo Nordisk ADR's Financial Health score is "great performance".
Check out Novo Nordisk ADR's recent earnings performance, and Novo Nordisk ADR's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar
Should you invest $2,000 in NVO right now?
Before you buy stock in NVO, consider this: ProPicks AI are 6 easy-to-follow model portfolios created by Investing.com for building wealth by identifying winning stocks and letting them run. Over 150,000 paying members trust ProPicks to find new stocks to buy – driven by AI. The ProPicks AI algorithm has just identified the best stocks for investors to buy now. The stocks that made the cut could produce enormous returns in the coming years. Is NVO one of them?
Reveal Undervalued Stocks Now